Gapping up
In reaction to strong earnings/guidance:
- CYOU +8.1%, ARLP +5.5%, MDR +5.4%, SOHU +3.5%, L +3.4%, SPOT +3.4%, NSP +1.4%, CADE +1.2%, SOGO +0.7%
Other news:
- LXRX +9.1% (Lexicon Pharma and Sanofi (SNY) confirm Zynquista approval in European Union for treatment of adults with type 1 diabetes)
- IR +3.7% (Gardner Denver (GDI) near deal to merge with IR unit, according to WSJ)
- VGR +2.3% (files to withdraw Registration Statement on Form S-3 due to error; re-files as shelf offering)
- DIS +2% (Following record breaking weekend for Avengers movie)
- LEN +1.8% (acquires control of 1,602 homesites across seven Raleigh communities from Level Homes)
- AVCO +1.4% (entered into placement agency agreement and securities purchase agreement)
- IMMU +1.3% (announced an exclusive license agreement to develop, register, and commercialize sacituzumab govitecan in Greater China, South Korea and certain Southeast Asian countries)
- IRBT +1.2% (modestly rebounding following last weeks's decline)
- AZN +1.2% (Lynparza receives positive EU CHMP opinion for 1st-line maintenance treatment of BRCA-mutated advanced ovarian cancer)
Analyst comments:
- TGT +3.1% (upgraded to Overweight from Equal Weight at Barclays)
- SFM +2.3% (upgraded to Buy from Hold at Deutsche Bank)
- AAL +1.5% (upgraded to Buy from Hold at Deutsche Bank)
- ADBE +1.5% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- VC +0.9% (upgraded to Hold from Underperform at Jefferies)
- ANGI +0.9% (initiated with an Overweight at JP Morgan)
- THS +0.8% (upgraded to Outperform from Market Perform at Wells Fargo)